Medtronic, a company specializing in medical technology, has received U.S. Food and Drug Administration (FDA) approval for its Simplera Sync sensor to be used with the MiniMed 780G insulin delivery system. The newly approved sensor is a disposable, fingerstick-free device that requires no overtape and features a simplified, two-step insertion process. This addition allows users more flexibility, as the MiniMed 780G system can now operate with both the Simplera Sync and Guardian 4 sensors. Medtronic plans to begin a limited launch of the Simplera Sync sensor in the United States in fall 2025.
The MiniMed 780G system features an adaptive algorithm that adjusts and corrects glucose levels every five minutes and includes Meal Detection technology that responds to rising glucose levels by automatically delivering insulin. Que Dallara, EVP and President of Medtronic Diabetes, said, "Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S." Medtronic’s latest approval supports its ongoing effort to provide smarter tools for managing diabetes and improving day-to-day usability for individuals who rely on insulin therapy.
